T1EV34.SA Teva Pharmaceutical Industries Limited
- Market cap
- BRL 273B
- P/E
- 104.5x
- P/B
- 6.47x
- ROE
- -5.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is T1EV34.SA undervalued?
Graham numberThe Graham number of Teva Pharmaceutical Industries Limited cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Teva Pharmaceutical Industries Limited fundamental analysis
No fundamental analysis for Teva Pharmaceutical Industries Limited yet.
Teva Pharmaceutical Industries Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and …
Full company profileTeva Pharmaceutical Industries Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Teva Pharmaceutical Industries Limited annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 14.9B | 15.8B | 16.5B | 17.3B | 16.2B |
| Gross Profit | 7.44B | 7.98B | 8.29B | 9.12B | 8.25B |
| Operating Income | -2.20B | 433M | -303M | 2.16B | 1.82B |
| EBITDA | -925M | 1.56B | 777M | 3.14B | 1.72B |
| Net Income | -2.45B | -559M | -1.64B | 1.41B | -414M |
| EPS | -2.20 | -0.50 | -1.45 | 1.23 | -0.36 |
| Balance Sheet | |||||
| Total Assets | 44.0B | 43.5B | 39.3B | 40.7B | 39.9B |
| Total Liabilities | 36.2B | 36.0B | 34.0B | 32.8B | 32.1B |
| Shareholders' Equity | 7.80B | 7.51B | 5.37B | 7.91B | 7.75B |
| Cash & Short-term Investments | 2.80B | 3.23B | 3.30B | 3.56B | 3.66B |
| Cash Flow | |||||
| Operating Cash Flow | 1.59B | 1.37B | 1.25B | 1.65B | 742M |
| Capital Expenditure | 548M | 526M | 498M | 501M | 544M |
| Free Cash Flow | 1.04B | 842M | 749M | 1.15B | 198M |
| Ratios | |||||
| ROE | -31.3% | -7.4% | -30.5% | 17.8% | -5.3% |
| ROA | -5.6% | -1.3% | -4.2% | 3.5% | -1.0% |
| Net Profit Margin | -16.4% | -3.5% | -9.9% | 8.2% | -2.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Teva Pharmaceutical Industries Limited dividends
Teva Pharmaceutical Industries Limited has not paid dividends in the last 4 fiscal years.
Who owns Teva Pharmaceutical Industries Limited
Ownership data of Teva Pharmaceutical Industries Limited is not available yet.
Teva Pharmaceutical Industries Limited company profile
- Company name
- Teva Pharmaceutical Industries Limited
- Ticker
- T1EV34.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 31,173
- Fiscal year end
- December
- Address
- 124 Dvora HaNevi?a St., Tel Aviv-Yafo, Israel, 6944020
- Phone
- 972 3 914 8213
- Website
- tevapharm.com
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Teva Pharmaceutical Industries Limited management
10- Mr. Richard D. FrancisPresident, CEO & Director · born 1968
- Mr. Eliyahu Sharon KalifExecutive VP & CFO · born 1974
- Dr. Eric A. Hughes M.D., Ph.D.Executive VP of Global R&D and Chief Medical Officer · born 1970
- Ms. Christine FoxExecutive VP of US Commercial & Head of Innovative Franchise · born 1969
- Mr. Evan Lippman M.B.A.Executive Vice President of Business Development · born 1970
- Mr. Matthew ShieldsExecutive Vice President of Global Operations · born 1975
- Mr. Amir WeissSenior VP & Chief Accounting Officer · born 1977
- Mr. Christopher J. Stevo CFASenior Vice President of Investor Relations & Competitive Intelligence
- Kathleen VeitSenior Vice President, Global Compliance & Ethics Officer
- Mr. Brian SavageInterim Chief Legal Officer